Immunservice Successfully Develops Innovative Immunostimulant

Immunservice is currently very successfully developing an innovative immunostimulant for subsequent use in papillomavirus-induced tumours in humans and – through our partner company 4Animals Alsterscience – also in animals.

Following a very positive interim analysis of immunological toxicology studies, today a nationwide study in Germany began in horses with so-called “sarcoids”, locally aggressive tumours that are triggered by papillomaviruses and very difficult to treat.

“The results of immunological studies in horses done so far are very promising, not just for animals but also for humans, where the virus can trigger cervical cancer and very difficult to treat tumours in mucous membranes,” said Prof. Huland, CEO of Immunservice.